MyFinsight
Home
Blog
About
Contact
Download
Download image
Intangible Royalty Assets
$132,534K
Financial Royalty Assets
$28,467K
Income From
Divestiture Transactions
$53,072K
License Fees
$6,988K
Service
$6,813K
Royalty
$161,001K
Contract Revenue And
Income
$66,873K
Material Sales Captisol
$40,213K
Gain (loss) from
change in fair value of...
$90,670K
Gain from short-term
investments
$18,433K
Interest income
$13,659K
Total revenue and
income
$268,087K
Total non-operating
income, net
$117,958K
Operating income (loss)
from continuing...
$41,002K
Interest expense
$4,715K
Other non-operating
expense, net
-$89K
Total operating costs
and expenses
$227,085K
Income before income
tax from continuing...
$158,960K
General and
administrative
$92,449K
Research and development
$81,182K
Amortization of intangibles
$32,708K
Cost of captisol
$14,549K
Financial royalty assets
impairment
$6,197K
Net income (loss)
from continuing...
$124,453K
Income tax expense
$34,507K
Net income (loss)
$124,453K
Back
Back
Income Statement
source: myfinsight.com
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)